IRulya Therapeutics Inc.
IRLA· Nasdaq
IRLAIRulya Therapeutics Inc.
Filed Nov 13, 2024 · 10-Q · 44 days after period end · 0001662774-24-000011
| Metric | Q3 2024 | Q3 2023 | Q3 2022 | Q3 2021 |
|---|---|---|---|---|
| Net Income | -$5.49M | -$5.35M | -$7.92M | -$21.71M |
| EPS Diluted | -$0.13 | -$0.15 | -$0.22 | -$0.73 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
IRulya Therapeutics Inc. · CIK 1662774 · Engraved from SEC EDGAR
ended Sep 30, 2024 · filed Nov 13, 2024 · 44 d after period end
